<DOC>
	<DOCNO>NCT00146003</DOCNO>
	<brief_summary>The purpose study demonstrate measurable improvement validate scale small population adult patient atopic dermatitis ( eczema ) .</brief_summary>
	<brief_title>Efalizumab Eczema</brief_title>
	<detailed_description>The study involve administration efalizumab ( previously approve psoriasis ) ten adult patient atopic dermatitis . Biologic plausibility rest similarity pathophysiology two condition . The drug ( efalizumab ) administer accord dose approve plaque psoriasis period 24 week . The subject self-administer efalizumab weekly measurement perform monthly basis . Efalizumab compare placebo drug .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Adults ( 18 year old ) atopic dermatitis 5 % body surface area involvement Investigator Global Assessment ( IGA ) score `` moderate '' worse In general good health wellcontrolled medical problem Ability provide write informed consent comply study assessment full duration study . If female childbearing potential , negative pregnancy test commitment use two form effective contraception ( birth control ) duration study necessary . If nonsterile male , commitment use two form effective contraception ( birth control ) duration study necessary . Normal platelet count Patients know hypersensitivity efalizumab component Pregnancy lactation Patients receive immunosuppressive agent Prior enrollment study Participation another simultaneous medical investigation trial IGA score `` mild , '' `` almost clear '' `` clear '' Systemic therapy atopic dermatitis , phototherapy topical therapy ( moisturizer ) within 1 week Medical condition would make use efalizumab unsafe ; would limit compliance study requirement ; would limit accurate assessment efficacy . Ongoing , active , serious infection History malignancy ( except excise basal squamous cell carcinoma skin )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>eczema</keyword>
	<keyword>atopic dermatitis</keyword>
	<keyword>efalizumab</keyword>
</DOC>